central nervous system of Diffuse large B-cell lymphoma
Conditions
Interventions
A:high-dose MTX and zanubrutini + lenalidomide + temozolomide + CD20 mAb alternately
B:zanubrutini + lenalidomide + temozolomide + CD20 mAb
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. According to the WHO classification of hematopoiesis and lymphoid tissue tumors in 2016, it was confirmed as diffuse large B-cell lymphoma by histological examination, and there was no focus outside the nervous system. 2. Male or female aged 18 or above at the time of signing informed consent. 3. Untreated diffuse large B-cell lymphoma of the central nervous system. 4. Measurable lesions, defined as >= 1 lesion of nervous system with the longest diameter > 1cm, or lymphoma cells in CSF. 5. Normal function of main organs: serum bilirubin = 3 months. 8. Can provide written informed consent, and understand and follow the requirements of the study.
Exclusion criteria
Exclusion criteria: 1. He was diagnosed with other malignant tumors in the previous 12 months; 2. Pregnant or lactating women; 3. Uncontrolled systemic fungal, bacterial, or viral infections (defined as symptoms / signs associated with infection, but not improved despite antibiotic or other treatment); 4. Known or suspected to be related to zebitinib; 5. Known human immunodeficiency virus (HIV) or active viral infection of hepatitis B or C; 6. Have a clear history of neurological or mental disorders, including epilepsy or dementia; 7. According to the judgment of the researcher, there are accompanying diseases that seriously endanger the safety of patients or affect patients to complete the study; 8. Taking other drugs at the same time or participating in clinical trials of other drugs one month before the test.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Head MRI;Cerebrospinal fluid flow cytometry; | — |
Secondary
| Measure | Time frame |
|---|---|
| routine blood test;Blood biochemistry;urine routine test;???? Bone marrow puncture; | — |
Countries
China
Contacts
Public ContactRong Fu
Tianjin Medical University General Hospital
Outcome results
None listed